Atlantic Edge Private Wealth Management’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$608K Buy
2,417
+1
+0% +$215 0.12% 96
2026
Q1
$526K Sell
2,416
-25
-1% -$5.55K 0.13% 93
2025
Q4
$558K Sell
2,441
-34
-1% -$7.75K 0.14% 90
2025
Q3
$573K Sell
2,475
-42
-2% -$8.55K 0.15% 89
2025
Q2
$467K Sell
2,517
-159
-6% -$29.6K 0.13% 93
2025
Q1
$561K Sell
2,676
-75
-3% -$14.6K 0.17% 89
2024
Q4
$489K Sell
2,751
-124
-4% -$22.8K 0.15% 90
2024
Q3
$568K Buy
2,875
+11
+0.4% +$2.05K 0.17% 91
2024
Q2
$491K Buy
2,864
+15
+0.5% +$2.48K 0.16% 92
2024
Q1
$519K Buy
2,849
+1,353
+90% +$233K 0.18% 91
2023
Q4
$232K Buy
+1,496
New +$218K 0.09% 115

Other funds holding ABBV

Atlantic Edge Private Wealth Management's ABBV Position: Q2 2026 in Review

Atlantic Edge Private Wealth Management increased its AbbVie (ABBV) stake by 0.04% in Q2 2026, buying an estimated $215 and bringing the position to 2,417 shares worth $608K. The position accounts for 0.12% of the portfolio, ranked #96.

Atlantic Edge Private Wealth Management first reported a position in ABBV in Q4 2023 and has held it in 11 quarters since. 1,805 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Atlantic Edge Private Wealth Management held 2,417 shares of AbbVie worth $608K as of Q2 2026.
  • Atlantic Edge Private Wealth Management bought 1 AbbVie share in Q2 2026, an estimated $215.
  • AbbVie made up 0.12% of Atlantic Edge Private Wealth Management's portfolio in Q2 2026, its #96 holding.
  • Atlantic Edge Private Wealth Management first reported a position in AbbVie in Q4 2023 and has held it in 11 quarters since.
  • 1,805 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Atlantic Edge Private Wealth Management's 13F filing for Q2 2026, filed 23 Jul 2026.